Every Form 4 that Quince (QNCX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.
Quince Therapeutics director David Lamond reported receiving a stock option grant covering 2,700 shares of common stock. The option has an exercise price of $0.947 per share and expires on June 11, 2036. All 2,700 shares underlying the option will vest in full on the one-year anniversary of the grant date. Following this award, Lamond holds options for 2,700 shares directly.
Quince Therapeutics director Christopher J. Senner received a grant of 2,700 stock options for common stock. These options have an exercise price of $0.947 per share and expire on June 11, 2036. All 2,700 options vest on the one-year anniversary of the grant date, and 2,700 derivative securities are reported as held directly after the transaction.
Quince Therapeutics, Inc. director and Chief Corp. Affairs Officer Brigette Roberts reported receiving multiple employee stock option awards for Quince common stock. On May 18, 2026, she was granted options covering several blocks of shares, including 6,837,319 options with an exercise price of $0.84 per share and additional grants such as 2,070,107 options at $0.09 per share, all classified as awards rather than market purchases or sales.
Footnotes explain these options were received in exchange for prior Orphai Therapeutics options under an Agreement and Plan of Merger involving Quince and Orphai entities. One option block begins vesting on May 21, 2026 in 36 equal monthly installments, conditioned on her continued service with the company. The filing shows only acquisitions of derivative awards, with no open-market stock trades.
Quince Therapeutics CEO and CMO Dirk Thye reported a new stock option grant. On January 23, 2026, he was granted an employee stock option to buy 1,000,000 shares of Quince Therapeutics common stock at an exercise price of $3.08 per share.
The filing shows Thye directly holds 1,000,000 derivative securities after this grant. The option vests in 48 equal monthly installments, with 1/48 vesting on the grant date and the remaining portions vesting on the first day of each subsequent month, so the award is scheduled to be fully vested by December 1, 2029.
Quince Therapeutics, Inc. reported that its President, Charles S. Ryan, received an employee stock option grant on January 23, 2026. The option gives him the right to buy 200,000 shares of common stock at an exercise price of $3.08 per share, with no cash paid for the grant itself.
The option vests in equal monthly installments over four years. According to the terms, 1/48th of the total shares vested on the grant date, and the remaining portions vest on the first day of each subsequent month so that all 200,000 shares are fully vested by December 1, 2029. After this grant, he directly beneficially owns 200,000 derivative securities in the form of these options.
Quince Therapeutics reported an insider equity award for executive Brendan Hannah, who serves as CBO, COO and CCO. On January 23, 2026, he received an employee stock option to buy 365,000 common shares at an exercise price of $3.08 per share, with the option expiring on January 23, 2036. The filing shows he holds 365,000 derivative securities after this grant, all owned directly.
The option vests in 48 equal monthly installments, with 1/48 of the shares vesting on the grant date and the remaining portions vesting on the first day of each subsequent month until full vesting on December 1, 2029. This reflects routine equity-based compensation for a senior officer rather than an open-market share purchase or sale.
Quince Therapeutics director Christopher J. Senner reported a grant of 21,810 stock options on January 2, 2026. The derivative award is a director stock option with a $3.00 exercise price and an expiration date of January 2, 2036, covering 21,810 shares of common stock. Following this grant, he beneficially owns 21,810 derivative securities directly.
The options will vest in equal quarterly installments over a one-year period. Senner elected to receive these options in lieu of the annual director cash retainer for 2026 under the company’s Outside Director Compensation Policy.
Quince Therapeutics director Margaret McLoughlin reported receiving a new stock option award. On 01/02/2026, she was granted a Director Stock Option (Right to Buy) covering 19,547 shares of common stock at an exercise price of $3 per share. The filing shows this as an acquisition of derivative securities held directly.
According to the footnote, the option vests in equal quarterly installments over a one-year period. McLoughlin elected to receive this stock option grant in lieu of the 2026 annual director cash retainer under the company’s Outside Director Compensation Policy, meaning this award represents her director compensation rather than an open-market transaction.
Quince Therapeutics director David Lamond reported receiving a grant of 29,423 director stock options on January 2, 2026. The options have an exercise price of $3.00 per share and relate to Quince common stock, with 29,423 derivative securities beneficially owned after the transaction. According to the filing, these options were granted in lieu of Lamond’s 2026 annual director cash retainer under the company’s Outside Director Compensation Policy and will vest in equal quarterly installments over a one-year period. The transaction is reported as a directly held derivative security.
Quince Therapeutics director June Bray received a new stock option grant. On 01/02/2026, Bray was granted director stock options covering 18,724 common shares at an exercise price of $3 per share, with no cash paid for the options themselves.
The options vest in equal quarterly installments over a one-year period, meaning the grant is tied to ongoing board service during 2026. Bray elected to receive this option award in lieu of the annual director cash retainer for 2026 under Quince Therapeutics' Outside Director Compensation Policy. Following this grant, Bray beneficially owns 18,724 derivative securities directly.
Quince Therapeutics, Inc. insider Dirk Thye, who serves as director and as CEO and CMO, reported a transfer of common shares dated 12/10/2025.
The reported transaction with code G involved 739,885 common shares at a stated price of $0, moving from direct to indirect beneficial ownership through the Thye Trust. After this transaction, Thye held 255,000 common shares directly and 739,885 common shares indirectly via the Thye Trust.